- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
Articles on Emergent Biosolutions, Inc. (EBS)
by latest | most commented
-
FDA, Clinical Trial Updates: Insmed, Jazz Pharma Await Key Results
-
PharmAthene: Game Changing Contract Ahead
-
VaxGen Still Looking to Return Value to Its Stockholders
-
Closing My Emergent BioSolutions Position
-
Race to Develop Bioterrorism Vaccine
-
20 'Bathwater Babies' and 3 'Dogs with Fleas' for the Week
-
Ugly Stock Stats from an Ugly Bear
-
Emergent Biosolutions - Yet Another Failed Breakout
-
Equities Generals Should Be Shot
-
Healthcare Reform, M&A Likely to Focus on Preventative Medicine
-
Emergent BioSolutions: Still a Bit Risky
-
Emergent Biosolutions Acquisition Is Dead, Stock Fairly Stable
-
2008 Stock Market: 51 Rays of Light
-
Until Proven Otherwise, Sticking with Emergent BioSolutions
-
40 Top Rated Emerging Bio-Pharma Stocks
-
The Few, The Proud, The Winners in 2008
-
Healthcare: Investing Trends for 2009
-
ETF Ideas Poised to Benefit from Pending Healthcare Reform
-
New Index of Preventive Medicine Companies
-
The Capitalism Distribution: Fat Tails in Motion
-
Emergent BioSolutions Looking Strong, Even on a Bad Day
-
New Emerging Biotech and Pharma Company Index
-
Emergent BioSolutions Files Shelf Registration
-
Emergent BioSolutions' Blowout Quarter
-
Bullish Outlook for Preventive Medicine Companies Reflected in New ETF
-
Emergent BioSolutions: Stellar Acting Stock
-
80% Down for the Year
-
Emergent BioSolutions: Surprising Value Play
-
Best and Worst Performing Stocks Seven Months Into 2008
-
Bioterrorism: Anthrax and Biotech Companies
-
Price Charts of Q1's Top Performing Stocks: BZP, IDIX, EBS, WLT
-
Q1's Best and Worst Performing Stocks
-
Emergent BioSolutions: Pipeline Dreams Can Become Nightmares
-
3 Undervalued Stocks with Strong Technicals: Emergent Biosolution, Boots & Coots, Gushan Environmental
-
The Wall Street Analyst Forum August Conference Schedule
-
Biotech Week In Review: Recovering Some Lost Ground
-
Biotech Day In Review: BioSimilar Cancer Drug Enters Trial
-
Biotech Day in Review: Allergan Expands Obesity Franchise
-
Russell 3000's Best, Worst Stocks Year to Date
-
Russell 3000's Best, Worst Stocks Year to Date
-
Biotech Rises To New Record High